EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset

Hannah Wallace iD, James Wick, Brendon L Neuen iD, Luke Buizen, Sunil V Badve, John Chalmers, Juliana de Oliveira Costa, Michael O Falster iD, Jeffrey T Ha, Meg J Jardine, Daniel Bekele Ketema, Jialing Lin iD und 10 weitere

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Hannah Wallace und 21 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of New South Wales, Eli Lilly Australia, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2 inhibitors) and glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) have cardio‐kidney‐metabolic benefit. This study aimed to understand the prevalence of prescription of SGLT2 inhibitors and GLP1‐RA among patients with T2DM with and without chronic kidney disease (CKD) in Australian primary care. Materials and Methods We conducted a retrospective, cohort study of adults with T2DM who attended primary care practices participating in MedicineInsight. The outcome of interest was the percentage of patients with CKD who received ≥1 prescription for an SGLT2 inhibitor or a GLP1‐RA (assessed separately) compared to those without CKD during 2020–2021. We also assessed prescriptions in a sub‐population of CKD patients who met trial inclusion criteria: SGLT2 inhibitor (estimated glomerular filtration rate [eGFR] ≥20 mL/min/1.73m 2 and urine albumin‐creatinine ratio [UACR] ≥22.6 mg/mmol) and GLP1‐RA (eGFR ≥50 to 33.9 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Renal Insufficiency, ChronicGlucagon-Like Peptide-1 Receptor AgonistsDrug PrescriptionsHypoglycemic AgentsHumansMaleFemaleAustraliaRetrospective StudiesMiddle AgedPrimary Health CareAgedPrevalencePractice Patterns, Physicians'Diabetic NephropathiesGlomerular Filtration Rate

Stichwörter der Autor:innen

chronic kidney diseaseglucagon‐like peptide‐1 receptor agonistsprimary caresodium‐glucose co‐transporter 2 inhibitorstype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • Western Health, Melbourne, Victoria, Australia.
  • Faculty of Medicine and Health, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Hannah Wallace, Brendon L Neuen, Michael O Falster, Jialing Lin, Takaya Sasaki, Mark Woodward, Sradha S Kotwal, Min Jun

Förderung

  • University of New South Wales
  • Eli Lilly Australia
  • Boehringer Ingelheim

Zitieren

APA

Wallace, H., Wick, J., Neuen, B. L., Buizen, L., Badve, S. V., Chalmers, J., de Oliveira Costa, J., Falster, M. O., Ha, J. T., Jardine, M. J., Ketema, D. B., Lin, J., Nelson, C., Pearson, S. A., Peiris, D., Rodgers, A., Sasaki, T., Woodward, M., Gallagher, M., …, & Jun, M. (2025). Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16608

Vancouver

Wallace H, Wick J, Neuen BL, Buizen L, Badve SV, Chalmers J, et al. Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16608

BibTeX
@article{Wallace2025,
  author = {Wallace, Hannah and Wick, James and Neuen, Brendon L and Buizen, Luke and Badve, Sunil V and Chalmers, John and de Oliveira Costa, Juliana and Falster, Michael O and Ha, Jeffrey T and Jardine, Meg J and Ketema, Daniel Bekele and Lin, Jialing and Nelson, Craig and Pearson, Sallie-Anne and Peiris, David and Rodgers, Anthony and Sasaki, Takaya and Woodward, Mark and Gallagher, Martin and Kotwal, Sradha S and Ronksley, Paul and Jun, Min},
  title = {Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16608}
}
Kostenlos starten →